CoChat

EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

This study was conducted to describe the modulation of plasma epidermal growth factor receptor (EGFR) ligands in EGFR-positive metastatic colorectal cancer (mCRC) patients during treatment with cetuximab and irinotecan and to explore the clinical implication of plasma levels' variations as potential biomarkers of benefit. Plasma amphiregulin (AR), epidermal growth factor (EGF), transforming growth factor-α, and heparin binding-EGF were assessed by ELISA in 45 chemorefractory mCRC patients, treated with cetuximab and irinotecan. Plasma levels were measured before and 1 h after the first administration of cetuximab, before and 1 h after the second administration, and before the third and the fifth cycles. KRAS and BRAF mutational status were determined. EGFR ligands' levels were differently modulated according to tumor KRAS and BRAF mutational status. In KRAS wild-type patients (n = 34), AR and EGF early increased and higher increases were significantly associated with worse clinical outcome. By adopting a specific cut-off value, patients with higher levels of AR 1 h after the first administration had significantly worse response rate, progression free survival, and overall survival. This hypothesis-generating study shows that EGFR ligands are significantly modulated by cetuximab plus irinotecan according to KRAS and BRAF mutational status, and they warrant further investigation as pharmacodynamic markers of resistance to anti-EGFRs.

Overview

Integrity signals

Registry

Crossref · 10.1007/s11523-013-0284-7

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 23 references

Research works printed but not linked: 1

  1. Van Cutsem E, Köhne CH, Hitre E et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408–1417 · DOI · Paper page

Cited by

See all 33

Metadata

Authors
Loupakis, F., Cremolini, C., Fioravanti, A., Orlandi, P., Salvatore, L., Masi, G., Schirripa, M., Di Desidero, T., Antoniotti, C., Canu, B., Faviana, P., Sensi, E., Lupi, C., Fontanini, G., Basolo, F., Di Paolo, A., Danesi, R., Falcone, A., & Bocci, G.
Affiliations
University of Pisa (IT)
Corresponding author
Bocci, Guido
Venue
Targeted Oncology
Published
2013-07-03
Volume
9
Issue
3
Pages
205-214
ISSN
  • 1776-2596 (ISSN-L)
  • 1776-260X
OpenAlex
W1984952201
Cited by
33
References
23
Citations by year
2024: 4 · 2023: 3 · 2022: 2 · 2021: 2 · 2020: 2 · 2019: 4 · 2017: 3 · 2016: 7 · 2015: 3 · 2014: 3
FWCI
2.32
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Targeted Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
EGFR ligands, pharmacodynamic biomarkers, metastatic colorectal cancer, cetuximab, irinotecan, amphiregulin, epidermal growth factor, transforming growth factor-alpha, heparin-binding EGF, KRAS mutation, BRAF mutation, anti-EGFR resistance, plasma biomarkers, progression-free survival, overall survival
MeSH terms
Cetuximab, Irinotecan, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Female, Humans, Ligands, Male, Middle Aged, Neoplasm Metastasis, Prospective Studies, Proto-Oncogene Proteins, Biomarkers, Tumor, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Disease-Free Survival, ras Proteins, Proto-Oncogene Proteins B-raf, Antibodies, Monoclonal, Humanized, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan. https://app.cochat.ai/papers/10.1007/s11523-013-0284-7
The paper
Loupakis, F., Cremolini, C., Fioravanti, A., Orlandi, P., Salvatore, L., Masi, G., Schirripa, M., Di Desidero, T., Antoniotti, C., Canu, B., Faviana, P., Sensi, E., Lupi, C., Fontanini, G., Basolo, F., Di Paolo, A., Danesi, R., Falcone, A., & Bocci, G. (2014). EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan. Targeted Oncology. https://doi.org/10.1007/s11523-013-0284-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.